Cup-W-Handle, imo the strongest bullish continuation pattern, Candidate cup has been formed, trading action suggests that a handle is forming catching its breath---consolidating after a 70-pt pop from the bottom of trading channel---on declining volume ERS will be on early Sept bought a bullish Oct CALL debit spread for a cost of $6.90; bto 260 CALL, sto 280 CALL, to be partially financed by selling an Aug PUT credit spread, 250/260 collecting a premium of $5.45 net/net my cost for these 2 spread is $1.45, which is my max risk Breakeven is ~ $261.45, max profit is capped at $8.55
earliest it gets reported is the next day after purchase, sometimes later. company providing update call tmr morning. let's see.
i still think googl makes the most sense as an acquirer for SDGR. compliments both their Google Cloud and life science stuff (Verily). i think if the founders were still actively managing there would be a higher chance (youtube, maps, android, etc.), but looks like pichai is more conservative. big tech are prob the only ones who can afford CRWD hehe.
btw, Saitou, both AMD and XLNX are up substantially lately, one can infer that the street is positive on the combination. fwiw, if i wasn't already making such a BIG play on FB, i'd pick up AMD for the ERS run
@saitou independent Data Monitoring Committee (DMC) for the Mino-Lok® Phase 3 Pivotal Superiority Trial has recommended proceeding with the trial as planned. The DMC did not identify any safety concerns and no modifications were recommended to the protocol-defined sample size or power to achieve the primary endpoint. I sold for now.
we should have, but that's the price of gambling on early termination. i'm ok with it, calculated risk. I sold off in case of dilution. will start accumulating again if it goes to $2.
ok listened to the call. cel sci staff sounded nervous and not the best speakers. not much new info except this - 40% of the population didn't take chemo. We already knew the result was statistically significant for this arm due to the P value, but confirms that it was a big arm and not a cherry picked outlier. bag holding for now.
in a similar boat. happy with the bets i made in may, cash fully deployed; going to keep sticking with them unless i see a really juicy opportunity.
in view of this seasonality dynamic, after a 14-pt pop on Mon, reaching an all-time high, there has been profit-taking on declining volume. it'd not b far-fetched to expect another 35 pt rise for FB
Right now in MO/T calls, T is up but probably not worth testing/entering now.. I took some risk on WISH, nothing exciting there yet (?), I don't know how much I like it but have been in/out some, it's hopefully a meme type play in the short-term. I have been lazy on other trades this last month and it showed, glad I didn't share those since it was all garbage.
Thank you. I agree on some nervousness there haha. I got in this morning and it recovered before close. I wonder what happens tomorrow...
I'm not expecting a quick rebound. Market obviously doesn't trust what cvm says of it's own chances. For it to go up in near term, my guess is these are the potential catalysts - a respected analyst starts coverage affirming what cvm is saying on fda approval chance; cvm publish results in peer reviewed journal and results are well received; cvm scores pre-BLA meeting with fda; funds start buying based on getting oncology experts to verify what cvm is saying. But who knows when these things happen exactly, and hopefully cvm isn't misleading shareholders. politically at least this seems like an easy, uncontroversial approval for FDA. If you are a non-chemo patient, multikene has proven in stat significant trial results to increase your odds of survival by ~30% without side effects. In fact it may be controversial for FDA to reject approval. But i'm not in the medical field, maybe there are other technicalities i'm not aware of.
